Maharashtra Herald

Endometriosis Market

The Endometriosis market growth is driven by factors like increase in the prevalence of Endometriosis, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Endometriosis market report also offers comprehensive insights into the Endometriosis market size, share, Endometriosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Endometriosis market size growth forward. 

Some of the key highlights from the Endometriosis Market Insights Report:

• Several key pharmaceutical companies, including AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, and others, are developing novel products to improve the Endometriosis treatment outlook. 
• Promising therapies in the Emdometriosis market are Linzagolix, Relugolix, and others.
• The endometriosis market size in 7MM is ~USD 1,920 million in 2021.
• The total Endometriosis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
• As per DelveInsight analysis, the Endometriosis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Endometriosis Market Landscape

Endometriosis Overview 

Endometriosis is a condition characterized by the presence of endometrial tissue outside the uterus, leading to recurring bleeding within these abnormal tissue growths. This happens because the ectopic endometrial tissue is responsive to hormonal changes, resulting in the formation of fibrous tissue. The disease primarily affects adolescents and women of reproductive age, and it is commonly associated with chronic pelvic pain and infertility. The most frequent sites where endometriosis occurs are the ovaries, pelvic peritoneum (the membrane lining the pelvic cavity), uterosacral ligaments, and torus uterus. However, atypical locations can also be observed, including the cervix, round ligaments, ureters, and nerves. In rare cases, endometriosis implants can even be found outside the pelvic area, such as in the upper abdomen, subphrenic fold, or abdominal wall.

Diagnosing endometriosis is often delayed, typically taking an average of 4 to 11 years from the onset of symptoms. This delay occurs due to the absence of a definitive test or biomarker for the disease and the overlap of symptoms with other gastrointestinal or gynecological conditions. The symptoms experienced by patients, including pain and discomfort during menstruation, may be mistakenly considered as normal physiological responses. To accurately diagnose endometriosis, a physician should gather a detailed medical history and perform a gynecological physical examination. The gold standard for diagnosis is laparoscopy, which involves exploring the abdominal cavity and obtaining a tissue sample for histological analysis. However, ultrasound and MRI can be used to detect ovarian endometriomas (cysts) and deep nodular forms of the disease.

The management of endometriosis requires a multidisciplinary approach. Treatment typically involves surgical intervention to diagnose and remove endometrial lesions, hormonal therapy to suppress the disease and prevent its recurrence and progression, pain management strategies offered by specialized pain centers, and pelvic therapy. Both surgical and medical treatments are equally effective in managing symptomatic endometriosis. Despite available pain treatments, recurrence of endometriosis is not uncommon. The choice of medical treatment depends on factors such as side effects, cost, and individual preferences. Initially, non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose combined oral contraceptive pills (COCPs) containing ethyl estradiol and progestins are commonly prescribed. If NSAIDs do not provide relief within three months, the next line of treatment options includes progestins (administered orally, via injection, or intra-uterine), androgens, and gonadotropin-releasing hormone agonists (GnRH) which effectively reduce moderate to severe pain associated with endometriosis.

Do you know the treatment paradigms for different countries? Download our Endometriosis Market Sample Report

Endometriosis Epidemiology Insights

• In 2021, the total prevalent cases of endometriosis were ~ 21,920,000 in the 7MM, which are expected to grow during the study period, i.e., 2019–2032.

Endometriosis Epidemiology Segmentation 

DelveInsight’s Endometriosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Endometriosis historical patient pools and forecasted Endometriosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Endometriosis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Endometriosis Prevalence 
• Age-Specific Endometriosis Prevalence 
• Gender-Specific Endometriosis Prevalence 
• Diagnosed and Treatable Cases of Endometriosis

Visit for more @ Endometriosis Epidemiological Insights

Recent Advances in the Treatment of Endometriosis

• FDA approves Myfembree for endometriosis pain: In August, 2022, Myovant announced the US Food and Drug Administration (FDA) has approved relugolix combination tablets (Myfembree; Myovant Sciences and Pfizer) for the treatment of moderate-to-severe endometriosis-associated pain. Previously, Myfembree was only approved for the management of uterine fibroid-related heavy menstrual bleeding in premenopausal women. “This approval is an important milestone reflecting Pfizer and Myovant’s commitment to women’s health in areas of significant unmet need,” said James Rusnak, MD, PhD, senior vice president, chief development officer, Internal Medicine and Hospital, Global Product Development at Pfizer. “We look forward to making Myfembree available to women with endometriosis and broadening their options in managing this complex disorder.”

Endometriosis Treatment Market 

The management of endometriosis requires a multidisciplinary approach with surgical diagnosis and debulking of disease load, hormonal treatment to suppress and delay recurrence and progression of disease, pain management strategies best provided by a pain center clinic that develops individualized care plans, and pelvic therapy. Symptomatic endometriosis is typically treated by surgical or medical treatment, both equally effective. Despite the available associated pain treatments, endometriosis recurrence is not uncommon. Medical treatment choices are based on side effect profile, cost, and personal preference. Non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose combined oral contraceptive pills (COCPs) such as ethyl estradiol and progestins are the first choice drugs. If patients do not respond to NSAIDs in 3 months, the second line of treatments is used, which includes progestins (oral, injectable, and intra-uterine), androgens, and gonadotropin-releasing hormone agonists (GnRH), which reduce moderate-to-severe pain of endometriosis.

The Endometriosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Endometriosis market trends by analyzing the impact of current Endometriosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

According to DelveInsight, the Endometriosis market in 7MM is expected to witness a major change in the study period 2019-2032.

Endometriosis Therapy Assessment

Linzagolix: ObsEva

ObsEva is currently advancing linzagolix, a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of endometriosis-associated pain. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately dose-dependently reducing estrogen production by the ovaries. Through previously reported results from linzagolix and sophisticated pharmacological modelling, it has been established that maintaining estradiol within a specific target range provides the optimal balance between reducing symptoms while mitigating bone density loss associated with excessive estradiol suppression. In 2015, ObsEva in-licensed Linzagolix from Kissei Pharmaceutical Co., which had completed several Phase 2a clinical trials in Japan.Currently, the drug is being evaluated in Phase III clinical trial evaluation for the treatment of Endometriosis.

Relugolix: Myovant Sciences

Relugolix Combination Tablet consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the treatment of endometriosis and for the prevention of pregnancy. Phase III clinical program for endometriosis consisted of two multinational, replicate pivotal clinical studies (SPIRIT 1 and SPIRIT 2) of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis. In January 2021, Myovant Sciences and Pfizer Inc. announced that the Phase III SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss.

Endometriosis Key Companies

• AbbVie
• Neurocrine Biosciences
• ObsEva
• Kissei Pharmaceuticals
• SWK
• Enteris BioPharma
• Bayer
• Hope Medicine
• Tiumbio
• Organon

For more information, visit Endometriosis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Endometriosis Market Report:

• 11 Years Forecast
• 7MM Coverage 
• Descriptive overview of Endometriosis, causes, signs and symptoms, diagnosis, treatment
• Comprehensive insight into Endometriosis epidemiology in the 7MM
• Endometriosis marketed and emerging therapies 
• Endometriosis companies
• Endometriosis market drivers and barriers 

Key Questions Answered in the Endometriosis Market Report 2032:

• What was the Endometriosis market share distribution in 2019, and how would it appear in 2032?
• What is the total Endometriosis market size and the market size by therapy across the 7MM for the study period (2019-32)?
• What are the important findings from 7MM, and which country will have the greatest Endometriosis market size from 2019-32?
• During the study period (2019-2032), at what CAGR is the Endometriosis market projected to expand at 7MM?

Table of Contents:

1 Endometriosis Market Key Comprehensive Insights 

2 Endometriosis Market Report Introduction

3 Competitive Intelligence Analysis for Endometriosis

4 Endometriosis Market Analysis Overview at a Glance

5 Executive Summary of Endometriosis

6 Endometriosis Epidemiology and Market Methodology

7 Endometriosis Epidemiology and Patient Population

8 Endometriosis Patient Journey

9 Endometriosis Treatment Algorithm, Endometriosis Current Treatment, and Medical Practices

10 Key Endpoints in Endometriosis Clinical Trials

11 Endometriosis Marketed Therapies 

12 Endometriosis Emerging Therapies

13 Endometriosis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Endometriosis

16 Endometriosis Market Key Opinion Leaders Reviews

18 Endometriosis Market Drivers

19 Endometriosis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Endometriosis Epidemiology 2032

DelveInsight’s “Endometriosis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Endometriosis Pipeline 2023

“Endometriosis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Endometriosis market. A detailed picture of the Endometriosis pipeline landscape is provided, which includes the disease overview and Endometriosis treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/